Results 101 to 110 of about 5,941 (192)

Randomized controlled trial comparing 7-day fexuprazan-based and 14-day rabeprazole-based triple therapies for Helicobacter pylori eradication. [PDF]

Medicine (Baltimore)
Kim JH, Nam SJ, Kim SH, Lee JH, Lee SH, Lee SJ, Park SC.   +6 more
europepmc   +1 more source

Bioequivalence of two rabeprazole formulations and pharmacokinetic variability by CYP2C19 genotype and sex in healthy Korean participants: A four-period replicated crossover study. [PDF]

Clin Pharmacol Drug Dev
Lee N, Cho JY, Kim B.
europepmc   +1 more source

The Effect of Food and the Proton Pump Inhibitor Rabeprazole on Binimetinib Pharmacokinetics in Healthy Participants. [PDF]

Clin Pharmacokinet
Hahn E, Piscitelli J, Huynh D, Chavira R, Wollenberg L, Reddy MB.   +5 more
europepmc   +1 more source

Modulation of Oxidative Stress and Nuclear Factor-κB- Associated Inflammatory Signaling by Rabeprazole in Acetic Acid-Induced Colonic Injury [PDF]

Turk J Gastroenterol
Özbek A, Yıldız M, Altınkaya E, Doğan HO, Özkaraca M, Ataseven H.   +5 more
europepmc   +1 more source

The effect of pH stability and aqueous solubility on the oral bioavailability of a novel antileishmanial agent. [PDF]

Eur J Pharm Sci
Nigro MR, Adebusuyi T, Kaur M, Xie H, Ma J, Olaleye E, Liang D.   +6 more
europepmc   +1 more source

Potential Implementation of Rabeprazole in Prevention of Acidity in GIT: Updated Mini-Review

Rabeprazole is a proton pump inhibitor. Pharmacodynamics data show rabeprazole can achieve optimal acid suppression since the first administration and can maintain this advantage in the following days of therapy. Moreover, rabeprazole has the highest pKa
Ritu Verma, Supriya Garg, Dipesh Kumar, Akash Kumar, Mohd. Shoaib, Manoj Kumar, Shubham Aashiyan, Triloki Prasad   +7 more
core  

Differential fracture risk among proton pump inhibitors in older adults: evidence network and pharmacovigilance validation. [PDF]

Front Pharmacol
Piao HL, Wu ZH, Zhou LY, Lai CH, Tang ZY, Yin WJ, Yi YH.   +6 more
europepmc   +1 more source

Beyond acid suppression: the multifaceted role of proton pump inhibitors in <i>Helicobacter pylori</i> eradication. [PDF]

Front Microbiol
Sroczyńska P, Krzyżek P.
europepmc   +1 more source

QSPR modelling of PPI drugs using hybrid topological indices. [PDF]

Front Chem
Monisha L, Jayagopal R.
europepmc   +1 more source

Proton pump inhibitors use and the risk of osteoporosis and fractures: A two-sample Mendelian randomization study. [PDF]

Medicine (Baltimore)
Li P, Wu R, Shi H.
europepmc   +1 more source